Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo - Sasakawa, Yuka; Naoe, Yoshinori; Inoue, Takeshi; Sasakawa, Tatsuya; Matsuo, Masahiko; Manda, Toshitaka; Mutoh, Seitaro (Biochemical pharmacology, 2002)
Keywords: Acetylation; Animals; Anti-Bacterial Agents - pharmacology; Anti-Bacterial Agents - therapeutic use; Antibiotics, Antineoplastic - pharmacology; Antibiotics, Antineoplastic - therapeutic use; Antineoplastic agents; Apoptosis; Biological and medical sciences; Cell Cycle - drug effects; Cell Differentiation - drug effects; Chemotherapy; Cholecalciferol - pharmacology; Cyclin-Dependent Kinase Inhibitor p21; Cyclins - biosynthesis; Cyclins - genetics; Depsipeptides; Disease Models, Animal; FK228; Gelsolin - biosynthesis; Gelsolin - genetics; Histone deacetylase inhibitor; Histone Deacetylase Inhibitors; Histones - metabolism; Humans; Leukemia - pathology; Lymphoma; Lymphoma - drug therapy; Lymphoma - pathology; Medical sciences; Mice; Mice, SCID; Neoplasm Transplantation; Peptides, Cyclic; Pharmacology. Drug treatments; Promoter Regions, Genetic - drug effects; Promoter Regions, Genetic - genetics; RNA, Messenger - biosynthesis; RNA, Messenger - drug effects; Tretinoin - pharmacology; U-937; U937 Cells; Xenograft Model Antitumor Assays; APL, acute promyelocytic leukemia; U-937; q-PCR, quantitative polymerase chain reaction; Lymphoma; vitamin D 3, 1α,25-dihydroxy-vitamin D 3; FK228; ChIP, chromatin immunoprecipitation; PE, phycoerythrin; Histone deacetylase inhibitor; ATRA, all- trans retinoic acid; HDAC, histone deacetylase; PTCL, peripheral T-cell lymphoma; TSA, trichostatin A; CTCL, cutaneous T-cell lymphoma; Antineoplastic agent; Human; Intraperitoneal administration; Rodentia; Enzyme inhibitor; Malignant hemopathy; In vitro; Biological activity; In vivo; Vertebrata; Chemotherapy; Mammalia; Treatment; Mouse; Lymphoproliferative syndrome; Animal; Established cell line; Mechanism of action; Tumor cell